Researchers at Duke and a spin-off company called Humacyte have been working on bioengineered blood vessels for almost fifteen years.
- Vaccine Education Summit
- Bitcoin Summit
- Ernie's Favorites
- THE R3VOLUTION CONTINUES
- "It's Not My Debt"
- Fascist Nation's Favorites
- Surviving the Greatest Depression
- The Only Solution - Direct Action Revolution
- Western Libertarian
- S.A.F.E. - Second Amendment is For Everyone
- Freedom Summit
- Declare Your Independence
- FreedomsPhoenix Speakers Bureau
- Wallet Voting
- Harhea Phoenix
- Black Market Friday
The operation, performed on Wednesday, June 5 at Duke University Hospital, was the bioengineered blood vessel's first clinical trial.
One of the major challenges in bioengineering human tissue for medical purposes is that the human body tends to reject implanted organs; the immune system will often attack these foreign cells as if they were harmful invaders.
The tissue of this artificially grown blood vessel is made from donated human cells. These cells are placed in a solution of amino acids, vitamins and nutrients, and grown around a tube-shaped mesh structure, causing the cells to form into the shape of a blood vessel.
Additional Related items you might find interesting:Related items:
News Link • World News
News Link • Transportation
Feature Article • General Opinion
News Link • Events: America